Arcutis Biotherapeutics (ARQT)
(Delayed Data from NSDQ)
$9.10 USD
-0.58 (-5.99%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $9.09 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.10 USD
-0.58 (-5.99%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $9.09 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Zacks News
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of 12.50% and 0.46%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sutro Biopharma (STRO) delivered earnings and revenue surprises of 22.37% and 2.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Equillium (EQ) delivered earnings and revenue surprises of 106.67% and 69.98%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 11.11% and 1.90%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health (GH) Moves 6.9% Higher: Will This Strength Last?
by Zacks Equity Research
Guardant Health (GH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.
Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why
by Zacks Equity Research
Arcutis (ARQT) rises 30.9% in a month after the label expansion of its marketed product, Zoryve cream 0.15%, for the AD indication in adult and pediatric patients aged six years and older.
Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data
by Zacks Equity Research
Interim data from an early-stage study shows that treatment with Lexeo's (LXEO) experimental gene therapy reduced signs of heart complications in patients with Friedreich's ataxia.
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
by Zacks Equity Research
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
by Zacks Equity Research
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.
Novo Nordisk (NVO) GLP-1 Drug Regarded Safe for Brain by Oxford
by Zacks Equity Research
Oxford study demonstrates that Novo Nordisk's (NVO) semaglutide is not associated with a risk of adverse neuropsychiatric outcomes compared with other antidiabetic medications over one year.
Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals
by Zacks Equity Research
Immutep (IMMP) jumps 15% on positive results from a late-stage study evaluating its candidate, efti, in combination with Keytruda to treat first-line head and neck squamous cell carcinoma patients.
Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why
by Zacks Equity Research
Kazia (KZIA) surges after positive data from a phase II/III study on its lead pipeline drug in patients with glioblastoma. Based on this data, it plans to seek an accelerated nod from the FDA.
Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan
by Zacks Equity Research
Pacira (PCRX) gains upon the inclusion of Exparel as one of only six qualifying non-opioid drugs to treat postsurgical pain in the proposed reimbursement rule, if adopted.
Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK
by Zacks Equity Research
Inovio (INO) soars 19% as its lead candidate, INO-3107, receives the innovative medicine tag under the U.K.'s Innovative Licensing and Access Pathway to treat recurrent respiratory papillomatosis.
United Therapeutics (UTHR) Completes Enrolment in IPF Study
by Zacks Equity Research
United Therapeutics' (UTHR) late-stage study is evaluating Tyvaso inhalation solution in IPF patients living outside the United States and Canada.
Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View
by Zacks Equity Research
Indivior (INDV) slashes financial guidance for 2024, primarily to reflect adverse sales conditions of its top-selling opioid drug. It will discontinue the sales of its schizophrenia drug.
FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease
by Zacks Equity Research
Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma
by Zacks Equity Research
Following the label expansion, AbbVie's (ABBV) Epkinly is the first bispecific antibody approved to treat relapsed/refractory (R/R) follicular lymphoma and R/R diffuse large B-cell lymphoma.
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
by Zacks Equity Research
Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
by Zacks Equity Research
Per argenx (ARGX), the label expansion to Vyvgart Hytrulo makes it the first FDA-approved medication with a novel mechanism of action to treat chronic inflammatory demyelinating polyneuropathy.
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
by Nalak Das
We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX.
OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
by Zacks Equity Research
Two late-stage studies, which evaluated Ovid Therapeutics' (OVID) experimental drug for two forms of epilepsy, fail to meet their primary endpoints.
Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Boston Scientific (BSX) have performed compared to their sector so far this year.